Co-Diagnostics Inc (Nasdaq: CODX), a US-based molecular diagnostics company, announced on Tuesday that it has named Ivory Chang as its new chief regulatory affairs officer.

Chang has served at various diagnostics companies including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background includes regulatory and registration submissions to major regulatory bodies around the world for infectious disease, oncology, point-of-care, in vitro diagnostics (IVD) and software diagnostic products.

Dwight Egan, Ccompany CEO, said: "We are pleased to welcome someone with Ms. Chang's vast industry experience to the management team at Co-Dx. We believe Ivory's skillset and impact in advancing our future regulatory submissions for our planned, expanding pipeline of products will help to further the Co-Dx vision of increasing the accessibility of state-of-the-art molecular diagnostic solutions, both for our legacy in vitro diagnostics products as well as our forthcoming Co-Dx PCR Home platform."